Dose Escalation Decisions
Dose Escalation Decisions - Related Videos
04:17
Dose Escalation: A Method for Developing Drug Resistance in Cancer Cells
0 Views •
2023
The video describes the development of drug resistance in cancer cells by exposing cells to escalating doses of a drug after calculating IC50 values of the drug previously with MTT assay. The sample protocol describes the step-by-step process of developing drug-resistant cells.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
08:34
Thinking Too Much Impairs Decision-Making
0 Views •
2023
Source: Peter Mende-Siedlecki & Jay Van Bavel—New York University When we are considering a tough choice between two or more attractive options, we often end up actively weighing the pros and cons of each alternative. By reflecting on their advantages and disadvantages, we attempt to fit a complex, subjective decision into an orderly set of criteria. However, research in psychology suggests that this sort of introspective approach might not always yield the most optimal outcomes.1 In other...
08:22
Decision-making and the Iowa Gambling Task
0 Views •
2023
Source: Laboratories of Jonas T. Kaplan and Sarah I. Gimbel—University of Southern California Decision-making is an important component of human executive function, in which a choice about a course of action or cognition is made from many possibilities. Damage to the inferior parts of the frontal lobes can affect a person's ability to make good decisions. However, while decision-making deficits can have a large impact on one's life, these deficits can be difficult to quantify in the laboratory.
01:24
Types of Decisions and the Decision Process
0 Views •
2025
The organizational buying process is structured and methodical, involving multiple stakeholders and requiring significant financial commitments. Unlike consumer purchasing, business buyers face complex decisions that demand a deep understanding of technical specifications and careful coordination among departments. These decisions are made within a framework that seeks to balance cost, quality, and efficiency and ensure long-term supplier relationships. Problem Recognition and Need...
FAQs
Investigators compare therapeutic effects and adverse events across successive dose levels to determine how responses change with increasing exposure. This comparison helps identify whether higher doses produce additional benefit, unacceptable toxicity, or limited added effect. The resulting dose-response information supports selection of an effective and tolerable exposure range for later neurological or psychiatric studies.
The brain’s sensitivity means that modest dose changes may influence cognition, behavior, or neural function in clinically important ways. Those effects can also be difficult to measure consistently. Consequently, escalation decisions must interpret treatment responses alongside adverse events and pharmacokinetic data rather than relying only on whether a target symptom appears to improve.
The decision depends on the response observed at the current dose, the frequency and severity of adverse events, pharmacokinetic findings, and predefined stopping criteria. Investigators may escalate when the exposure remains tolerable and additional benefit is plausible, maintain the dose when evidence is still being evaluated, or stop when safety limits or stopping rules are reached.
Pharmacokinetic data show how treatment exposure changes with dose and provide context for interpreting therapeutic effects and adverse events. A response observed at one dose may have different significance depending on the resulting exposure. Reviewing these data at each level helps investigators connect administered dose with biological exposure and judge whether further escalation is justified.
Investigators administer a defined dose level, assess therapeutic effects and adverse events, and review pharmacokinetic findings. They then compare the observations with predefined stopping criteria and decide whether to increase the dose, retain the current level, or stop escalation. Repeating this structured review across dose levels helps characterize exposure while protecting research participants.
They are used while researchers characterize how different exposure levels relate to benefit and tolerability before later studies. In neuroscience, the approach is especially relevant when therapies may alter cognition, behavior, or neural function. The resulting evidence helps guide subsequent investigation of neurological and psychiatric treatments and supports selection of doses suitable for continued clinical research.